Actively Recruiting
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Led by Peking University Cancer Hospital & Institute · Updated on 2025-03-03
60
Participants Needed
1
Research Sites
224 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.
CONDITIONS
Official Title
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years, male or female
- Histopathologically confirmed acral melanoma (stage III or II)
- No prior systemic anti-tumor drug treatment
- Measurable disease based on RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate organ function
- Life expectancy longer than 12 weeks
- Provided written informed consent
You will not qualify if you...
- Receiving or previously received chemotherapy, radiation, targeted therapy, or immunotherapy
- Known allergy to apatinib, temozolomide, or Camrelizumab
- Other current or previous malignant tumors except cured skin basal cell carcinoma or cervical carcinoma in situ
- Active or history of autoimmune disease
- Unstable systemic diseases such as serious infection, uncontrolled diabetes, unstable heart conditions, cerebrovascular events, heart failure, serious arrhythmia, or liver, kidney, or metabolic disease
- Received live vaccine within 4 weeks before starting study medication
- Pregnant or breastfeeding
- Deemed unsuitable by the principal investigator or treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
J
Jun Guo
CONTACT
L
Lili Mao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here